N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £2 million (before expenses) through a placing of 25,000,000 new ordinary shares of 0.4p each in the Company at an issue price of 8p per Placing Share. The Placing, which was significantly oversubscribed, was undertaken by SP Angel Corporate Finance LLP.
The net proceeds of the Placing will be used for:
· the extension of the formulation and current stability work covering DNA and mRNA formulations;
· research on and evaluation of an additional asset to add to the Company portfolio;
· business development driven by study results pending over next six months; and
· ongoing working capital.
Application for Admission
The Placing has been conducted utilising the Company’s existing share authorities. Application has been made for the Placing Shares to be admitted to trading on AIM (“Admission”) and it is expected that Admission will take place and that trading will commence on AIM at 8.00 a.m. on or around 14 December 2020. Once issued, the new Ordinary Shares will rank pari passu with the Company’s existing ordinary shares.
Total Voting Rights
Following Admission, the enlarged issued share capital of the Company will comprise 181,080,349 Ordinary Shares of 0.4 pence each. The Company does not hold any ordinary shares in treasury. Consequently, 181,080,349 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.
Nigel Theobald, Chief Executive of N4 Pharma, commented: “We are delighted with the positive response to our recent formulation work. With vaccines and their delivery very much in the public consciousness we continue to grow our data package to present Nuvec® as a viable delivery technology solution to improve the delivery, storage and transportation of multiple existing and new vaccines.
“Whilst we are well funded for all existing work streams these additional funds will enable us to plan for follow on studies and more product focussed experiments as we move towards collaborations.”
